720 related articles for article (PubMed ID: 31234784)
1. Assessing the cost-effectiveness of HPV vaccination strategies for adolescent girls and boys in the UK.
Datta S; Pink J; Medley GF; Petrou S; Staniszewska S; Underwood M; Sonnenberg P; Keeling MJ
BMC Infect Dis; 2019 Jun; 19(1):552. PubMed ID: 31234784
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of sex-neutral HPV-vaccination in Sweden, accounting for herd-immunity and sexual behaviour.
Wolff E; Elfström KM; Haugen Cange H; Larsson S; Englund H; Sparén P; Roth A
Vaccine; 2018 Aug; 36(34):5160-5165. PubMed ID: 30017146
[TBL] [Abstract][Full Text] [Related]
3. The value of male human papillomavirus vaccination in preventing cervical cancer and genital warts in a low-resource setting.
Sharma M; Sy S; Kim JJ
BJOG; 2016 May; 123(6):917-26. PubMed ID: 26176301
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness analysis of the introduction of the human papillomavirus vaccine in Honduras.
Aguilar IB; Mendoza LO; García O; Díaz I; Figueroa J; Duarte RM; Perdomo G; Garcia AG; Janusz CB
Vaccine; 2015 May; 33 Suppl 1():A167-73. PubMed ID: 25919157
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness and epidemiological impact of gender-neutral HPV vaccination in Spain.
Linertová R; Guirado-Fuentes C; Mar-Medina J; Teljeur C
Hum Vaccin Immunother; 2022 Nov; 18(6):2127983. PubMed ID: 36347243
[TBL] [Abstract][Full Text] [Related]
6. Prevention of HPV-related cancers in Norway: cost-effectiveness of expanding the HPV vaccination program to include pre-adolescent boys.
Burger EA; Sy S; Nygård M; Kristiansen IS; Kim JJ
PLoS One; 2014; 9(3):e89974. PubMed ID: 24651645
[TBL] [Abstract][Full Text] [Related]
7. Comparison of two dose and three dose human papillomavirus vaccine schedules: cost effectiveness analysis based on transmission model.
Jit M; Brisson M; Laprise JF; Choi YH
BMJ; 2015 Jan; 350():g7584. PubMed ID: 25567037
[TBL] [Abstract][Full Text] [Related]
8. Comparing the cost-effectiveness of two- and three-dose schedules of human papillomavirus vaccination: a transmission-dynamic modelling study.
Laprise JF; Drolet M; Boily MC; Jit M; Sauvageau C; Franco EL; Lemieux-Mellouki P; Malagón T; Brisson M
Vaccine; 2014 Oct; 32(44):5845-53. PubMed ID: 25131743
[TBL] [Abstract][Full Text] [Related]
9. Incremental cost-effectiveness evaluation of vaccinating girls against cervical cancer pre- and post-sexual debut in Belgium.
Demarteau N; Van Kriekinge G; Simon P
Vaccine; 2013 Aug; 31(37):3962-71. PubMed ID: 23777952
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness analysis of a gender-neutral human papillomavirus vaccination program in the Netherlands.
Simons JJM; Vida N; Westra TA; Postma MJ
Vaccine; 2020 Jun; 38(30):4687-4694. PubMed ID: 32451211
[TBL] [Abstract][Full Text] [Related]
11. Optimal human papillomavirus vaccination strategies to prevent cervical cancer in low-income and middle-income countries in the context of limited resources: a mathematical modelling analysis.
Drolet M; Laprise JF; Martin D; Jit M; Bénard É; Gingras G; Boily MC; Alary M; Baussano I; Hutubessy R; Brisson M
Lancet Infect Dis; 2021 Nov; 21(11):1598-1610. PubMed ID: 34245682
[TBL] [Abstract][Full Text] [Related]
12. Is expanding HPV vaccination programs to include school-aged boys likely to be value-for-money: a cost-utility analysis in a country with an existing school-girl program.
Pearson AL; Kvizhinadze G; Wilson N; Smith M; Canfell K; Blakely T
BMC Infect Dis; 2014 Jun; 14():351. PubMed ID: 24965837
[TBL] [Abstract][Full Text] [Related]
13. Health and Economic Impact of a Tender-Based, Sex-Neutral Human Papillomavirus 16/18 Vaccination Program in the Netherlands.
Qendri V; Bogaards JA; Berkhof J
J Infect Dis; 2017 Jul; 216(2):210-219. PubMed ID: 28586466
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of HPV vaccination in the context of high cervical cancer incidence and low screening coverage.
Võrno T; Lutsar K; Uusküla A; Padrik L; Raud T; Reile R; Nahkur O; Kiivet RA
Vaccine; 2017 Nov; 35(46):6329-6335. PubMed ID: 28899625
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness analysis of human papillomavirus vaccination in South Africa accounting for human immunodeficiency virus prevalence.
Li X; Stander MP; Van Kriekinge G; Demarteau N
BMC Infect Dis; 2015 Dec; 15():566. PubMed ID: 26652918
[TBL] [Abstract][Full Text] [Related]
16. Cost-Effectiveness Analysis of Human Papillomavirus Vaccination in Adolescent Girls in Taiwan.
Tang CH; Cheng WF; Jiang JH; You SL; Huang LW; Hsieh JY; Mukherjee P; Van Kriekinge G; Lee C
Asian Pac J Cancer Prev; 2019 May; 20(5):1377-1387. PubMed ID: 31127896
[TBL] [Abstract][Full Text] [Related]
17. Estimating the clinical benefits of vaccinating boys and girls against HPV-related diseases in Europe.
Marty R; Roze S; Bresse X; Largeron N; Smith-Palmer J
BMC Cancer; 2013 Jan; 13():10. PubMed ID: 23298365
[TBL] [Abstract][Full Text] [Related]
18. Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States.
Kim JJ; Goldie SJ
BMJ; 2009 Oct; 339():b3884. PubMed ID: 19815582
[TBL] [Abstract][Full Text] [Related]
19. Estimating the cost-effectiveness profile of a universal vaccination programme with a nine-valent HPV vaccine in Austria.
Boiron L; Joura E; Largeron N; Prager B; Uhart M
BMC Infect Dis; 2016 Apr; 16():153. PubMed ID: 27084683
[TBL] [Abstract][Full Text] [Related]
20. Public health impact and cost effectiveness of routine and catch-up vaccination of girls and women with a nine-valent HPV vaccine in Japan: a model-based study.
Cody P; Tobe K; Abe M; Elbasha EH
BMC Infect Dis; 2021 Jan; 21(1):11. PubMed ID: 33407188
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]